Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

By Agnes Y Y Lee, P. Kamphuisen, Guy Meyer, Rupert Bauersachs, M. Janas, M. Jarner, A. Khorana. Journal of the American Medical Association (JAMA), 2015

611 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/8857cb29b78e9464aa69e0b8a40e0b4011b87a28

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Ay
2. Agnes Y. Y. Lee
3. A. Khorana
4. L. Hicks
5. A. Leavitt
6. W. Wiercioch
7. P. Alonso-Coello
8. R. Morgan

Citations in the corpus

• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, methodology): “From these reviews, we identified 8 eligible RCTs that fulfilled our inclusion criteria and measured outcomes relevant to this question.(314-319) In all studies, LMWH was administered over 3 to 6 months, and the outcomes were assessed during that time frame.”
• Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, neutral): “AT9 did not address if there was a role for aspirin, or antiplatelet therapy generally, in the treatment of VTE.”